BioNTech Defies Broader Market Slump as Restructuring and Buyback Win Investor Favour
11.06.2026 - 20:35:42 | boerse-global.de
BioNTech closed Thursday at €76.60, up 2.41%, on a day the Dow Jones shed nearly 1,000 points and the Nasdaq lost almost 2%. That decoupling is the clearest signal yet that the market is beginning to price in a very different company from the pandemic-era juggernaut. The stock remains 27.6% below its 52-week high of €105.80, but the relative strength is drawing attention.
Two parallel moves are driving the narrative shift. The company slashed 1,860 jobs in May, a painful but overdue end to the headcount expansion that accompanied the Covid-19 vaccine boom. Simultaneously, it launched a $1 billion share buyback programme on 8 June 2026, authorised by the supervisory and management boards on 7 May. The programme runs until May 2027 and is capped at 10% of the company's share capital — a maximum of 24.9 million American Depositary Shares. An independent bank will handle trading decisions, and the repurchased shares will be used to improve capital efficiency.
The job cuts are the sharper edge of a broader pivot from pandemic-focused operations to a leaner oncology powerhouse. Fixed costs are coming down as management prioritises the pipeline over expansion at any cost. For investors, it is a belated but credible move towards fiscal discipline. The buyback reinforces that message, signalling that BioNTech views its own equity as undervalued at current levels — roughly €74.60 at the time of the programme's start, more than 30% below the January 2026 high.
That discount is visible in the technicals. The relative strength index stood at 44.1 after Thursday's rally, well clear of oversold territory, while the 52-week low of €68.35 from March sits about 12% below current levels. But the stock still trades around 10.6% below its 200-day moving average of €85.65 — not yet in a sustainable uptrend, but showing signs of basing.
Should investors sell immediately? Or is it worth buying BioNTech?
Analysts are more optimistic. The consensus price target is €106.40, implying nearly 39% upside from Thursday's close. The consensus view is that the market is systematically undervaluing BioNTech's long-term mRNA capabilities and oncology assets.
Chief among those assets is BNT327, or pumitamig, a bispecific antibody co-developed with Bristol Myers Squibb. It targets both PD-L1 and VEGF-A simultaneously, aiming to boost the immune response against tumours while cutting off a cancer's blood supply. The FDA granted it orphan-drug designation for small-cell lung carcinoma in 2025. Phase 3 trials are underway for small-cell lung cancer and triple-negative breast cancer. Encouraging interim data from the ROSETTA-Lung-02 study showed a 100% disease control rate in patients with advanced non-small-cell lung cancer when combined with chemotherapy. A phase 3 extension of that study is already enrolling.
BioNTech's goal is to have several oncology drugs on the market by 2030. The company holds a war chest that allows it to fund those programmes without distress. The market capitalisation of roughly €19 billion reflects considerable skepticism about that timeline — and leaves room for a recovery if the pipeline delivers.
BioNTech at a turning point? This analysis reveals what investors need to know now.
Not all noise is positive. The company still faces the same headwinds as partner Pfizer, which reported a 59% drop in Comirnaty revenue last quarter. But where Pfizer is fighting a rearguard action, BioNTech is reshaping its cost base and its product horizon. Thursday's outperformance in a falling market is the first sign that the toughest part of the transition may be behind it. The path to the consensus target is long, but for the first time in months, the direction of travel is clear.
Ad
BioNTech Stock: New Analysis - 11 June
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
